Mpex Pharmaceuticals
	Developer of therapies for antibiotic resistance. The company offers MP-376, a proprietary formula of levofloxacin that is developed clinically as a maintenance therapy for the prevention of bacterial exacerbations in patients with cystic fibrosis and chronic obstructive pulmonary diseases. It also provides inhibitors of bacterial multi-drug resistant efflux pumps, which are source of drug resistance in gram-negative pathogens, such as Pseudomonas aeruginosa and gram-positive pathogens, such as methicillin-resistant staphylococcus aureus. It has a strategic alliance with GlaxoSmithKline.
	['', 'antibiotic resistance therapy', ' ', 'gram-negative organism', ' antibiotic ', 'aerosol formulation', ' ', 'bacterial exacerbation', '']
Pinnacle Pharmaceuticals
	Developer of therapeutics for pain management, urology, antibiotics and oncology space by leveraging its supramolecular chemistry platform and drug formulation technology. The company also develops synergistic compounds for current antibiotic regimes to treat patients suffering from infections refractory to the current gold-standard and therapeutics for various infectious disease indications, including methicillin resistant staphylococcus aureus and vancomycin resistant enterococci.
	['', 'pain management', ' ', 'oncology space', ' ', 'supramolecular chemistry platform', ' ', 'drug formulation technology', ' ', 'synergistic compound', ' ', 'antibiotic regime', '']
Arpida
	Developer of antimicrobial drugs for the treatment of infectious diseases. The companyâ€™s lead product is intravenous iclaprim, an antibiotic product that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus.
	['', 'antimicrobial drugs', ' antibiotic ', 'methicillin-resistant', ' ', 'staphylococcus aureus', '']
